According to the Second International Consensus Guidelines on the Management of BK Polyomavirus in Kidney Transplantation there is insufficient data to evaluate the efficacy of switching to mTOR inhibitors for treating BKPyV-DNAemia or biopsy-proven BKPyV-nephropathy [23]. This evidence concerns the gene MTOR and kidney disorder.